Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine.
- Author:
Yue-mei HU
1
;
Han-hua FANG
;
Gui-hua GAO
;
Xue-feng ZHANG
;
Yi-ju ZHANG
;
Shi-wei ZHU
;
Feng-cai ZHU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Age Factors; Antibody Formation; immunology; Canada; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; immunology; Female; Humans; Infant; Injections; Male; Middle Aged; Orthomyxoviridae; immunology; Time Factors; Viral Vaccines; administration & dosage; adverse effects; immunology; Young Adult
- From: Chinese Journal of Epidemiology 2005;26(7):503-506
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the safety and immunogenicity of Canada split influenza virus vaccine.
METHODSCluster samples were by randomly chosen and divided into split vaccination group and homoimported influenza vaccination group.
RESULTSAfter injection, fever-reaction and local reaction rates of 'trial' group were found as 3.69% and 1.75% respectively, but no statistical significance was found when compared with 'control' group. However the antibody positive rates of 'trail' and 'control' groupsappeared statistically significant (H1N1: 96.8% vs. 92.3%, H3N2: 95.8% vs. 90.2%, B: 52.3% vs. 62.3%). For geometric mean titer (GMT) of type H1N1, H3H2 and B antibody, 'trial' group and 'control' group increased 22.4, 16.8, 8.2 and 21.2, 12.5 and 7.4 times respectively. The antibody protective rates of type H1N1, H3N2 and B were 99%, 99% and 53.9% for 'trial' group, and 96.2%, 98.4% and 62.3% for 'control' but with no statistically significant difference.
CONCLUSIONInfluenza split vaccine made in Shire company in Canada was safe and with good immunogenicity.
